Sector News

Catalent snaps up Bettera Brands for US$1B to expand gummy and softgel offerings

September 5, 2021
Life sciences

Catalent is addressing the rising demand for alternative delivery formats with the US$1 billion acquisition of Bettera Brands, which offers nutritional gummies, softgels and lozenges. The definitive agreement is with Highlander Partners, under which it will acquire Bettera Holdings, the parent company of Bettera Brands.

The transaction is expected to close by the end of 2021 and is subject to customary closing conditions.

The acquisition is a key strategic move for Catalent’s Consumer Health business, according to Dr. Aris Gennadios, president, softgel and oral technologies, Catalent.

“As an innovator in softgel and oral technologies, Catalent has a long-standing presence in the rapidly expanding consumer health and nutraceutical marketplace. This way, we can offer customers more product development opportunities and add manufacturing capacity in this dynamic and growing segment.”

“This acquisition allows us to significantly accelerate the growth of our consumer health business and offer customers access to the substantial potential in gummies, soft chews and lozenges, which are all experiencing double-digit growth,” adds Gennadios.

Expanding manufacturing capabilities
Bettera Brands, which is headquartered in Texas, maintains four US manufacturing operations in California, Virginia, New Jersey and Indiana.

Highlander formed Bettera Brands through a series of four acquisitions beginning in 2017 and shaped it into a manufacturer of high-quality ingredient nutritional vitamins, minerals and supplements.

“In 2017, we started with a simple investment thesis of creating manufacturing capabilities around fortified/functional products in consumer-preferred formats,” says Jeff Hull, president and CEO of Highlander Partners.

As consumers have become increasingly health-conscious, functional products in gummy, soft chew and lozenge delivery forms have developed and grown to become a significant part of the market,” he argues.

“Given the substantial advances in delivery technologies, along with the increased health awareness, consumers are embracing these experiential formats as part of their everyday wellness routine.”

Jeff Partridge, a partner with Highlander who also served as Bettera’s CEO, adds that the company has identified a need early on and quickly assembled assets and a management team to capitalize on the demand and growth.

“Developing certified facilities, maintaining strict compliance standards and creating highly technical R&D capabilities was not an easy task.”

Expansion moves
Catalent recently signed a commitment letter with the Science-Based Target initiative, joining the list of companies setting actionable, science-based greenhouse gas emission reduction targets to limit global warming.

The company previously released Optigel DR, a design for delayed-release softgel capsules that eliminates the need for a second coating step in the manufacturing process. This is done by combining pectin with gelatin.

This launch inspired Hofseth BioCare to develop a delayed-release formulation of its OmeGo fish oil along with Catalent.

Moreover, Catalent launched CosmoPod Duo, a softgel capsule for the delivery of topical skin treatments. Based on the company’s CosmoPod unit-dose twist-off capsule technology, the capsule features segregated compartments to accommodate two formulations into a single twist-off solution.

Edited by Kristiana Lalou

Source: nutritioninsight.com

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).